0001415889-24-023183.txt : 20240910 0001415889-24-023183.hdr.sgml : 20240910 20240910203146 ACCESSION NUMBER: 0001415889-24-023183 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240906 FILED AS OF DATE: 20240910 DATE AS OF CHANGE: 20240910 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Palleiko Benjamin L CENTRAL INDEX KEY: 0001366244 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 241291253 MAIL ADDRESS: STREET 1: C/O KALVISTA PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, BLD 200, STE 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Palleiko Ben DATE OF NAME CHANGE: 20060615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 form4-09112024_120942.xml X0508 4 2024-09-06 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001366244 Palleiko Benjamin L C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 true true false false CHIEF EXECUTIVE OFFICER 0 Common Stock 2024-09-06 4 M 0 15625 A 258152 D Common Stock 2024-09-09 4 S 0 7352 12.1901 D 250800 D Restricted Stock Unit 2024-09-06 4 M 0 15625 0 D Common Stock 15625 218751 D Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.19 to $12.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on June 6, 2024, subject to continued service through each vesting date. /s/ Benjamin L. Palleiko 2024-09-10